Skip to content
10-Q

Quarterly Report

X4 Pharmaceuticals, Inc XFOR

0001628280-25-021358

← back to feed
Filed
May 1, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 28, 2025 5.79M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $40.26M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $55.7M
Current Liabilities Q1 2025 · Mar 31, 2025 $25.88M
Current Liabilities Q1 2025 · Dec 31, 2024 $32.88M
Total Liabilities Q1 2025 · Mar 31, 2025 $107.07M
Total Liabilities Q1 2025 · Dec 31, 2024 $124.3M
Current Assets Q1 2025 · Mar 31, 2025 $95.7M
Current Assets Q1 2025 · Dec 31, 2024 $112.18M
Total Assets Q1 2025 · Mar 31, 2025 $130.01M
Total Assets Q1 2025 · Dec 31, 2024 $146.45M
Shares Diluted restated Q1 2025 · Mar 31, 2024 6.67M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$33.6M
Stockholders Equity Q1 2025 · Mar 31, 2024 $1.04M
Stockholders Equity Q1 2025 · Dec 31, 2023 $51.1M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$7.77
Eps Basic restated Q1 2025 · Mar 31, 2024 −$7.77
Sga Expense Q1 2025 · Mar 31, 2024 $17.44M
Rd Expense Q1 2025 · Mar 31, 2024 $19.85M
Net Income Q1 2025 · Mar 31, 2024 −$51.77M
Operating Income Q1 2025 · Mar 31, 2024 −$37.29M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $0
Revenue Q1 2025 · Mar 31, 2024 $0